New Swedish research initiative targets obesity and metabolic diseases
June 19, 2025 / obesity research initiative / metabolic disease treatment / AstraZeneca Gothenburg partnership / cardiovascular risk factors / Swedish life sciences investment
A new SEK 200M Swedish initiative by AstraZeneca, University of Gothenburg, and partners will explore obesity and metabolic diseases, aiming to uncover disease mechanisms and develop targeted, safe, and effective treatments over a 10-year collaborative research program.
Beyond the Breakthrough: Building a Long-Term Obesity and Cardiometabolic Care Ecosystem
June 20, 2025 / obesity treatment personalization / cardiometabolic disease care / Roche obesity research / obesity biomarkers diagnostics / long-term weight loss strategy
Roche is advancing a holistic, personalized ecosystem for long-term obesity and cardiometabolic care, integrating diagnostics and therapeutics to tailor treatments, improve adherence, and address the complex biology and heterogeneity underlying obesity and its associated comorbidities.
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss
June 21, 2025 / GLP-1 weight loss / ecnoglutide clinical trial / obesity cardiometabolic treatment / MASLD therapy innovation / ADA 2025 obesity data
Ecnoglutide, a novel GLP-1 receptor agonist, significantly reduced weight and improved key cardiometabolic risk factors in adults with obesity in the Phase 3 SLIMMER trial, offering targeted metabolic benefits through selective cAMP pathway activation.
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data
June 23, 2025 / weight cycling risks / heart failure and obesity / MASLD and BMI fluctuation / type 2 diabetes weight change / cardiometabolic disease prevention
Weight cycling increases the risk of heart failure by over 50% and raises the likelihood of sleep apnea, MASLD, and type 2 diabetes by nearly 30%, independent of baseline BMI, according to a large Vanderbilt retrospective cohort study.
Plant-Based Caloric Restriction Superior for Weight Loss, Other Metabolic Benefits
June 23, 2024 / plant-based calorie restriction / PB-CRD obesity treatment / metabolic benefits weight loss / glucose metabolism diet / body fat reduction diet
A 12-week trial found that plant-based calorie-restricted diets (PB-CRDs) led to similar weight loss as standard CRDs but offered superior metabolic benefits, including reduced body fat, improved glucose metabolism, and lower uric acid levels in adults with obesity.
How early-life factors raise lifelong diabetes risks in youth
June 19, 2025 / pediatric cardiometabolic health / childhood obesity risk / metabolic syndrome assessment / cardiometabolic app ObMetrics / adolescent health screening
Early-life obesity, socioeconomic disadvantage, and genetic and environmental factors significantly raise lifetime risks for type 1 and type 2 diabetes in youth, contributing to early-onset vascular complications, insulin resistance, and higher morbidity and mortality, particularly in disadvantaged populations.
Amycretin delivers unprecedented weight loss in early trial for obesity treatment
June 23, 2025 / amycretin weight loss / GLP-1 agonist obesity / triple agonist therapy / obesity clinical trial results / metabolic disease treatment
Amycretin, a novel triple-receptor agonist targeting GLP-1, amylin, and calcitonin pathways, achieved up to 24.3% weight loss in early trials with manageable side effects, positioning it as a promising next-generation therapy for obesity and related metabolic conditions.
New oral drug shows promise for type 2 diabetes and obesity without side effects
June 23, 2025 / oral diabetes treatment / obesity drug innovation / β2 agonist metabolism / muscle-preserving weight loss / GLP-1 alternative therapy
A novel oral β2 agonist developed by Karolinska Institutet shows promise in type 2 diabetes and obesity, improving blood glucose and fat metabolism without reducing appetite or muscle mass, unlike GLP-1 drugs. Phase I results confirm favorable tolerability.
Tracking microbial rhythms reveals new target for treating metabolic diseases
June 18, 2025 / microbiome metabolism therapy / time-restricted feeding benefits / bile salt hydrolase obesity / gut bacteria insulin sensitivity / metabolic disease microbiome
UC San Diego researchers identified a microbial enzyme, bile salt hydrolase (BSH), that mimics time-restricted feeding benefits—improving metabolism and reducing body fat—by restoring gut microbial rhythms disrupted by high-fat diets. The findings suggest new microbiome-targeted therapies for metabolic diseases.
YuvaBio strikes obesity drug discovery deal with Northstrive
June 20, 2024 / mitochondrial dysfunction obesity / AI drug discovery diabetes / cardiometabolic disease therapy / YuvaBio MitoNova platform / metabolic health small molecules
Yuva Biosciences and Northstrive Biosciences have partnered to develop novel obesity and type 2 diabetes therapies by targeting mitochondrial dysfunction using YuvaBio’s AI-driven MitoNova platform, aiming to address root metabolic causes through small molecule discovery and experimental validation.
Hyderabad-based biotech startup Utopia Therapeutics raises $1.5 million
June 23, 2025 / obesity vaccine immunotherapy / metabolic disease biotech India / UT009 lipid antigen therapy / Utopia Therapeutics funding / next-generation obesity treatment
Hyderabad-based Utopia Therapeutics raised $1.5M to advance UT009, a novel obesity vaccine targeting lipid-associated antigens. The immunotherapy aims to reduce fat accumulation and improve metabolic health, representing a potential paradigm shift in chronic disease treatment.
EMA Recommends Rezdiffra for MASH Liver Fibrosis
June 20, 2025 / Rezdiffra / MASH liver fibrosis treatment / EMA resmetirom approval / thyroid hormone receptor beta / metabolic liver disease therapy
The EMA has recommended conditional approval of Rezdiffra (resmetirom) as the first treatment for noncirrhotic MASH with liver fibrosis in adults. Rezdiffra targets thyroid hormone receptor-beta to reduce liver fat, inflammation, and fibrosis.
Millions of people suffer from non-alcohol buildup of fat in the liver. A team approach offers critical help.
June 20, 2025 / MASH treatment / MASLD liver disease / resmetirom approval EU / GLP-1 liver therapy / metabolic liver transplant care
A multidisciplinary clinic at UCHealth is using team-based care and new therapies like resmetirom to treat and manage MASLD and MASH, emphasizing prevention, transplant support, and emerging strategies such as GLP-1 agonists and personalized, genetics-driven treatment.
European regulator recommends approval of Madrigal’s MASH drug
June 20, 2025 / resmetirom approval / MASH treatment / liver fibrosis drug / Madrigal Pharmaceuticals
The European Medicines Agency recommended resmetirom (Rezdiffra) for adults with noncirrhotic MASH and liver fibrosis, based on Phase 3 success. It may become the first approved treatment for MASH in the European Union, addressing a major unmet need.
Adipose tissue ageing: implications for metabolic health and lifespan
June 23, 2025 / adipose ageing / metabolic health / senolytics therapy / GLP-1 interventions
Ageing significantly alters adipose tissue structure and function, impacting systemic metabolism and increasing risk for diseases like fatty liver and cardiovascular conditions. Interventions such as caloric restriction and GLP-1 agonists may help preserve adipose health and extend lifespan.
Fatty Liver, But Not Liver Damage, Common in Type 2 Diabetes
June 18, 2025 / type 2 diabetes / fatty liver disease / MASLD risk / liver fibrosis / obesity screening
A new study found that 59% of people with type 2 diabetes had fatty liver (MASLD), though only a small fraction showed signs of early cirrhosis. Obesity significantly increased progression risk, underscoring the need for targeted screening and intervention.
Myth-busting study shows controversial seed oils reduce inflammation
June 21, 2025 / ‘linoleic acid / seed oils health / cardiometabolic risk / inflammation biomarkers / type 2 diabetes prevention
A new study using blood biomarkers shows that higher linoleic acid levels—found in seed oils—are associated with reduced inflammation, improved glucose metabolism, and lower cardiometabolic risk, challenging claims that seed oils are harmful to heart and metabolic health.
Semaglutide benefits extend to type 1 diabetes
June 23, 2025 / semaglutide benefits / type 1 diabetes treatment / automated insulin delivery / glycemic control / weight loss therapy
Semaglutide significantly improved time in glycemic range, reduced body weight, and maintained low hypoglycemia rates in adults with type 1 diabetes and obesity using automated insulin delivery systems, according to the ADJUST-T1D trial results presented at ADA 2025.
The role of broad bean albumin 1b on GIP and GLP-1 mediated alterations to glucose metabolism in diabetic mice
June 23, 2025 / broad bean albumin / GLP-1 secretion / GIP stimulation / glucose metabolism improvement / functional foods diabetes
Broad bean albumin 1b (BA1b) improved glucose metabolism in diabetic mice by enhancing GIP and GLP-1 secretion through VDAC1 gene upregulation, suggesting potential as a functional food component for metabolic health improvement.